News

According to the company, its focus on therapeutics that target the epithelial-mesenchymal transition (EMT) in cancer supports the development of BGB324. BerGenBio CEO Richard Godfrey said inhibition of

VGX-100 is a human antibody that acts against the human VEGF-C protein. VGX-100 when combined with Avastin and chemotherapy, demonstrated reduced tumour growth and tumour spread, and improved

Exparel is a multivesicular liposomal combined therapy product including bupivacaine with a delivery technology – DepoFoam. Exparel with DepoFoam delivers bupivacaine for an extended period of time, providing

The agreement is said to provide Charles River’s clients with services including GMP-compliant protein analytics, detailed protein characterization and lot release testing. Through the partnership, the companies can

The grants will be allocated through the Foundation’s Translational Research Acceleration Program. One of the projects under the program involves the use of gene therapy to resurrect and

Oxo derivatives are used in automotive, construction, cosmetics, pharmaceutical and personal care products. The move is said to provide a boost to Oxea’s growth strategy in China. Oxea

As per the agreement, Mayo Clinic and Oxford BioMedica will take up clinical studies on glaucoma treatment using Oxford BioMedica’s LentiVector gene delivery technology. The technology expresses a

The European Commission (EC) has granted approval to Eli Lilly and Company for the use of Alimta (pemetrexed for injection) as a single agent for continuation maintenance therapy

Enoxaparin, a generic equivalent to Sanofi-aventis’ Lovenox is a low molecular weight heparin used to treat deep vein thrombosis and prophylaxis in unstable angina and non-Q-wave myocardial infarction.